|
ZSCAN5A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.84939999980926E-07 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
5.554100E-04 |
| Stage1-vs-Stage3 |
2.854800E-01 |
| Stage1-vs-Stage4 |
2.57719999996464E-06 |
| Stage2-vs-Stage3 |
5.387600E-04 |
| Stage2-vs-Stage4 |
6.58929999453051E-08 |
| Stage3-vs-Stage4 |
2.575900E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
9.23919999951117E-07 |
| Normal-vs-Asian |
1.62447832963153E-12 |
| Caucasian-vs-AfricanAmerican |
8.034600E-01 |
| Caucasian-vs-Asian |
3.957600E-01 |
| AfricanAmerican-vs-Asian |
5.595000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
7.175200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(81-100Yrs) |
3.680000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.642200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.331600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.087400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.793200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.996200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.070600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.5827999999839E-06 |
| Classical-VS-Follicular |
4.15839999989842E-07 |
| Classical-VS-Other |
3.553200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.24631424572408E-12 |
| Tall-VS-Other |
2.505800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.200730E-03 |
| Follicular-VS-Normal |
3.18020000333874E-08 |
| Other-VS-Normal |
4.04040000345773E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.233500E-04 |
|
|
